PCSK9 and musculoskeletal system disorder: Furthermore, since estrogen competes with statins for transporters and enzymes, and female gender has previously been deemed as a risk factor for musculoskeletal disorders (Faubion et al., 2019), PCSK9 inhibitors have the potential as a better alternative for women.